Weikang Pharmaceutical announced that revenue for the third quarter of 2026 was 52.1859 million yuan, up 42.01% year on year; net loss was 822,300 yuan, down 98.62% year on year. Revenue for the first three quarters of 2026 was 178 million yuan, up 17.86% year on year; net loss was 23.779 million yuan, down 81.37% year on year; after deducting non-net loss of 23.1351 million yuan, loss of 81.07% year on year. As of the end of the reporting period, the company's special securities account held 2,739 million shares, accounting for 1.89% of the total share capital.

Weikang Pharmaceutical announced that revenue for the third quarter of 2026 was 52.1859 million yuan, up 42.01% year on year; net loss was 822,300 yuan, down 98.62% year on year. Revenue for the first three quarters of 2026 was 178 million yuan, up 17.86% year on year; net loss was 23.779 million yuan, down 81.37% year on year; after deducting non-net loss of 23.1351 million yuan, loss of 81.07% year on year. As of the end of the reporting period, the company's special securities account held 2,739 million shares, accounting for 1.89% of the total share capital.